Dr. Marshall on Key Data from the DESTINY-Gastric02 Trial in HER2+ Gastric Cancer

Video

In Partnership With:

John L. Marshall, MD, discusses key findings from the phase 2 DESTINY-Gastric02 trial examining fam-trastuzumab deruxtecan-nxki in patients with HER2-positive gastric cancer.

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, professor, Medicine and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses key findings from the phase 2 DESTINY-Gastric02 trial (NCT04014075) examining fam-trastuzumab deruxtecan-nxki (Enhertu) in patients with HER2-positive gastric cancer.

The antibody-drug conjugate elicited a significant response rate of 38% in this patient population; this included several complete responses, according to Marshall. This is significant because HER2 targeting after first-line therapy in gastric cancer has not previously proven to be successful, Marshall explains.

Furthermore, the high response rate observed in subsequent lines therapy suggest that the agent is a potent HER2-targeted treatment, Marshall adds. The data further emphasize the need for adequate molecular profiling for patients with gastric cancer, so that HER2 status can be confirmed, and appropriate treatments can then be administered, Marshall concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD